6533b81ffe1ef96bd1278fdf

RESEARCH PRODUCT

Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes

Björn LemmerJürgen BohlThomas G. Ohm

subject

Malemedicine.medical_specialtyAdenylate kinaseCyclasechemistry.chemical_compoundAlzheimer DiseaseReference ValuesInternal medicineIsoprenalinemedicineHumansCyclic adenosine monophosphateSenile plaquesMolecular BiologyAgedAged 80 and overGuanylyl ImidodiphosphateForskolinChemistryGeneral NeuroscienceColforsinIsoproterenolBrainKineticsEndocrinologyPostmortem ChangesSecond messenger systemFemaleNeurology (clinical)Cyclase activityAdenylyl CyclasesDevelopmental Biologymedicine.drug

description

Cyclic adenosine monophosphate (cAMP) is an adenylate cyclase borne second messenger involved in basic metabolic events. The beta-adrenoceptor sensitive adenylate cyclase was studied in post-mortem hippocampi of controls and Alzheimer patients. Virtually identical subsets of each hippocampus homogenate were stimulated by 100 mumol isoprenaline, Gpp(NH)p and forskolin, respectively, in presence of an ATP-regenerating system. The determination of cAMP formed was carried out by means of a radioassay. The observed significant 50% reduction in basal as well as in stimulated adenylate cyclase activity in Alzheimer's disease is negatively correlated with semiquantitative evaluations of amyloid plaques (P less than 0.05) but not with neuritic plaques, neurofibrillary tangles or neuropil threads. This reduction in enzyme activity is obviously not due to simple cell loss alone. It is likely that the crucial point of the observed functional disturbance is at the level of the catalytic unit of the adenylate cyclase, since the same degree of reduction is maintained at all steps of the signal cascade.

https://doi.org/10.1016/0006-8993(91)90512-t